According to Watson Pharmaceuticals's announcement, the cumulative deviation value of the company's stock price increase reached more than 20% during the three consecutive trading days of August 13, August 14, and August 17, 2026, which is an abnormal fluctuation in stock trading. After verification, the company, the controlling shareholder, and actual controller had no important matters that should be disclosed but not disclosed, and the controlling shareholder or actual controller did not trade the company's shares during the period of abnormal stock fluctuations. As of the close of trading on August 17, 2026, the company's rolling price-earnings ratio was 53.46 times and the net price-earnings ratio was 4.07 times, higher than the rolling price-earnings ratio of 28.89 times and the net price-earnings ratio of 2.68 times for the pharmaceutical manufacturing industry during the same period. The company's current production and operation situation is stable, and there have been no significant changes. The research project is underway, and the 2026 semi-annual report will be disclosed on August 21, 2026.

According to Watson Pharmaceuticals's announcement, the cumulative deviation value of the company's stock price increase reached more than 20% during the three consecutive trading days of August 13, August 14, and August 17, 2026, which is an abnormal fluctuation in stock trading. After verification, the company, the controlling shareholder, and actual controller had no important matters that should be disclosed but not disclosed, and the controlling shareholder or actual controller did not trade the company's shares during the period of abnormal stock fluctuations. As of the close of trading on August 17, 2026, the company's rolling price-earnings ratio was 53.46 times and the net price-earnings ratio was 4.07 times, higher than the rolling price-earnings ratio of 28.89 times and the net price-earnings ratio of 2.68 times for the pharmaceutical manufacturing industry during the same period. The company's current production and operation situation is stable, and there have been no significant changes. The research project is underway, and the 2026 semi-annual report will be disclosed on August 21, 2026.